Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

27 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Emergency contraceptive tablet to help prevent an unintended pregnancy

There is good news for college students as they head back to campus this fall. A new emergency contraceptive, Plan B® One-Step (levonorgestrel) tablet, 1.5 mg, is now available at the local pharmacy for all students 17 and older.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Low-dose estrogen effective for metastatic breast cancer

When estrogen-lowering drugs no longer control metastatic breast cancer, the opposite strategy might work. Raising estrogen levels benefited 30 percent of women whose metastatic breast cancer no longer responded to standard anti-estrogen treatment, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.

19 Aug 2009

U.S. District Court rules against Lilly regarding Gemzar patent

Eli Lilly and Company today announced that the U.S. District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment.

17 Aug 2009

New guidance on novel H1N1 influenza for K-12 schools

The Secretary of Health today released guidance on Novel H1N1, also known as swine flu, for elementary and secondary schools in an effort to keep kids and staff healthy and flu-free this school year.

17 Aug 2009

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition.

12 Aug 2009

Investigational, orally-inhaled therapy effective in treating migraines

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

12 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Nausea News and Research

Further Reading

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Retigabine's Phase IIa clinical trial preliminary results announced

Emergency contraceptive tablet to help prevent an unintended pregnancy

FDA issues complete response letter regarding the NDA for carisbamate

Nutra Pharma launches Cobroxin for chronic pain relief

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

New production technology to develop vaccine for norovirus

Low-dose estrogen effective for metastatic breast cancer

U.S. District Court rules against Lilly regarding Gemzar patent

New guidance on novel H1N1 influenza for K-12 schools

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Investigational, orally-inhaled therapy effective in treating migraines

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News